Cognivia, a Mont-Saint-Guibert, Belgium-based AI company dedicated to innovating pharmaceutical and biotech clinical research, raised €15.5M in funding.
Backers included Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d’Investissement) and WE (Wallonie Entreprendre).
The company intends to use the funds to deploy its predictive clinical trial solutions that decode the relationship between patient traits and behaviors, thus expediting the development of innovative treatments for patients globally.
Led by CEO Dominique Demolle, Cognivia combines quantification of patient psychology with artificial intelligence (AI)/machine learning (ML) to improve measurement of therapeutic efficacy in clinical trials – and beyond. Its technologies predict patient behavior and treatment response in clinical trials using predictive ML powered algorithms based on a quantitative understanding of patient psychological traits, expectations and beliefs collected via its own and specific questionnaires developed toward that objective.
Commenting on the news, Dominique Demolle said: “With this investment and the welcomed addition of new members to our operational team and Company Board and Strategic Advisory Committee, to be announced soon, we are poised to accelerate our efforts in delivering groundbreaking approaches that empower clinicians, researchers and industries to make informed, data-driven decisions, ultimately enhancing outcomes for patients and stakeholders worldwide.”
FinSMEs
18/04/2024